{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:31:06Z","timestamp":1790623866617,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002655","name":"Terry Fox Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.nucmedbio.2020.02.001","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T11:47:44Z","timestamp":1580730464000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [64Cu]Cu-NOTA-panitumumab F(ab\u2032)2 alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib"],"prefix":"10.1016","volume":"84-85","author":[{"given":"Amanda J.","family":"Boyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Jiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongli","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Hedley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond M.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0010","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0015","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jamcollsurg.2004.01.008","article-title":"Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors","volume":"198","author":"Cleary","year":"2004","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0020","first-page":"343","article-title":"Imaging preoperatively for pancreatic adenocarcinoma","volume":"6","author":"Pietryga","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0025","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2174\/138945012800564158","article-title":"Targeting EGFR in pancreatic cancer treatment","volume":"13","author":"Troiani","year":"2012","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.nucmedbio.2014.10.009","article-title":"MicroPET\/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using 64Cu-NOTA-panitumumab F(ab\u2032)2 fragments","volume":"42","author":"Boyle","year":"2015","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0035","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1021\/acs.molpharmaceut.9b00422","article-title":"MicroSPECT\/CT imaging of cell-line and patient-derived EGFR-positive tumor xenografts in mice with panitumumab fab modified with hexahistidine peptides to enable labeling with 99mTc(I) tricarbonyl complex","volume":"16","author":"Ku","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0040","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1021\/acs.molpharmaceut.7b01000","article-title":"Panitumumab modified with metal-chelating polymers (MCP) complexed to 111In and 177Lu-an EGFR-targeted theranostic for pancreatic cancer","volume":"15","author":"Aghevlian","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0045","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1021\/acs.molpharmaceut.8b01040","article-title":"Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NRG mice with panitumumab modified with metal-chelating polymers complexed to 177Lu","volume":"16","author":"Aghevlian","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0050","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/bjc.2014.215","article-title":"Oncogenic KRAS signalling in pancreatic cancer","volume":"111","author":"Eser","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0055","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1073\/pnas.93.13.6814","article-title":"Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu","volume":"93","author":"Connett","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0060","article-title":"Maximum tolerated dose and large tumor radioimmunotherapy studies of 64Cu-labeled monoclonal antibody 1A3 in a colon cancer model","volume":"5","author":"Connett","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0065","first-page":"3608","article-title":"Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model","volume":"5","author":"Lewis","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0070","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2967\/jnumed.115.167155","article-title":"Immuno-PET imaging and radioimmunotherapy of 64Cu-\/177Lu-labeled anti-EGFR antibody in esophageal squamous cell carcinoma model","volume":"57","author":"Song","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0075","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2967\/jnumed.118.225045","article-title":"64Cu-intraperitoneal radioimmunotherapy: a novel approach for adjuvant treatment in a clinically relevant preclinical model of pancreatic cancer","volume":"60","author":"Yoshii","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0080","first-page":"226","article-title":"The clinical implications of gemcitabine radiosensitization","volume":"7","author":"Doyle","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0085","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ijc.20004","article-title":"Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft","volume":"109","author":"Gold","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0090","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/bjc.2011.382","article-title":"The role of PARP in DNA repair and its therapeutic exploitation","volume":"105","author":"Javle","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0095","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2967\/jnumed.112.111534","article-title":"Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor","volume":"54","author":"Al-Ejeh","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0100","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1158\/1078-0432.CCR-14-0048","article-title":"Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma","volume":"20","author":"Al-Ejeh","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0105","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","article-title":"Elimination mechanisms of therapeutic monoclonal antibodies","volume":"11","author":"Tabrizi","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ijc.28006","article-title":"Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition","volume":"133","author":"Chang","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MPA.0b013e3181c15963","article-title":"Phenotype and genotype of pancreatic cancer cell lines","volume":"39","author":"Deer","year":"2010","journal-title":"Pancreas"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0120","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/15384101.2016.1138188","article-title":"Cytokinetic effects of Wee1 disruption in pancreatic cancer","volume":"15","author":"Chang","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0125","first-page":"436","article-title":"Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides","volume":"20","author":"Miller","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0130","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/ijc.2910150505","article-title":"Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas","volume":"15","author":"Lieber","year":"1975","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0135","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1083\/jcb.98.6.2148","article-title":"Receptor-mediated endocytosis of epidermal growth factor by hepatocytes in the perfused rat liver: ligand and receptor dynamics","volume":"98","author":"Dunn","year":"1984","journal-title":"J Cell Biol"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev.ph.51.030189.000435","article-title":"Epidermal growth factor and the kidney","volume":"51","author":"Fisher","year":"1989","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/cbir.1994.1001","article-title":"The role of growth factors in gastrointestinal cell proliferation","volume":"18","author":"Alison","year":"1994","journal-title":"Cell Biol Int"},{"issue":"Suppl. 1","key":"10.1016\/j.nucmedbio.2020.02.001_bb0150","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3747\/co.v17is1.615","article-title":"Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer","volume":"17","author":"Fakih","year":"2010","journal-title":"Curr Oncol"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0155","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nm.3070","article-title":"Epidermal growth factor regulates hematopoietic regeneration after radiation injury","volume":"19","author":"Doan","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0160","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.V85.9.2385.bloodjournal8592385","article-title":"Transforming growth factor-alpha (TGF-alpha) in human bone marrow: demonstration of TGF-alpha in erythroblasts and eosinophilic precursor cells and of epidermal growth factor receptors in blastlike cells of myelomonocytic origin","volume":"85","author":"Waltz","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0165","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(24)37962-5","article-title":"Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor","volume":"288","author":"Lin","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0170","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4161\/cbt.11.12.15528","article-title":"Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy","volume":"11","author":"Bryan","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.nucmedbio.2020.02.001_bb0175","series-title":"PET theranostics for molecular imaging and radioimmunotherapy of pancreatic cancer","first-page":"1","author":"Boyle","year":"2019"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805119305050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805119305050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:28:47Z","timestamp":1760848127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805119305050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":35,"alternative-id":["S0969805119305050"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2020.02.001","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [64Cu]Cu-NOTA-panitumumab F(ab\u2032)2 alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2020.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}